Evotec and GV have invested in Carrick Therapeutics, a company commercialising research from institutions including Cambridge and Oxford universities and Imperial College London.
Ireland-based cancer-focused biotechnology company Carrick Therapeutics raised $95m today from a consortium including GV, the corporate venturing arm of conglomerate Alphabet, and drug discovery company Evotec.
The round was co-led by Arch Venture Partners, the VC firm spun out of Chicago University’s tech transfer office, and investment firm Woodford Investment Management. It further featured Cambridge Enterprise Seed Funds, backed by Cambridge’s commercialisation arm, university venturing fund Cambridge Innovation Capital and Lightstone Ventures.
An insider said: “Evotec does a lot of…
